{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:22:07Z","timestamp":1740108127924,"version":"3.37.3"},"reference-count":8,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2014,8,7]],"date-time":"2014-08-07T00:00:00Z","timestamp":1407369600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Strahlenther Onkol"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1007\/s00066-014-0728-8","type":"journal-article","created":{"date-parts":[[2014,8,6]],"date-time":"2014-08-06T04:37:13Z","timestamp":1407299833000},"page":"1084-1085","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Strahlentherapie (4\u00a0Gy vs. 24\u00a0Gy) von Patienten mit indolentem Non-Hodgkin-Lymphom"],"prefix":"10.1007","volume":"190","author":[{"given":"Klaus","family":"Herfarth","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laila","family":"K\u00f6nig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,8,7]]},"reference":[{"key":"728_CR1","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.radonc.2011.05.013","volume":"100","author":"L Lowry","year":"2011","unstructured":"Lowry L, Smith P, Qian W et al (2011) Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: a randomised phase III trial. Radiother Oncol 100:86\u201392","journal-title":"Radiother Oncol"},{"key":"728_CR2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/hon.2900120102","volume":"12","author":"G Ganem","year":"1994","unstructured":"Ganem G, Lambin P, Socie G et al (1994) Potential role for low dose limited-field radiation therapy (2\u2009\u00d7\u20092 grays) in advanced low-grade non-Hodgkin\u2019s lymphomas. Hematol Oncol 12:1\u20138","journal-title":"Hematol Oncol"},{"key":"728_CR3","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1200\/JCO.2003.09.542","volume":"21","author":"RL Haas","year":"2003","unstructured":"Haas RL, Poortmans P, de Jong D et al (2003) High response rates and lasting remissions after low-dose involved field radiotherapy in indolent lymphomas. J Clin Oncol 21:2474\u20132480","journal-title":"J Clin Oncol"},{"key":"728_CR4","doi-asserted-by":"crossref","unstructured":"Hoskin PJ, Kirkwood AA, Popova B et al (2014) 4\u00a0Gy versus 24 Gy radiotherapy for patients with indolent lymphoma (FORT): a randomised phase 3 non-inferiority trial. Lancet Oncol. http:\/\/dx.doi.org\/10.1016\/S1470-2045(14)70036-1 . Zugegriffen: Feb. 2014","DOI":"10.1016\/S1470-2045(14)70036-1"},{"key":"728_CR5","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.ijrobp.2013.04.035","volume":"86","author":"CE Fasola","year":"2013","unstructured":"Fasola CE, Jones JC, Huang DD, Le QT, Hoppe RT, Donaldson SS (2013) Low-dose radiation therapy (2\u00a0Gy\u2009\u00d7\u20092) in the treatment of orbital lymphoma. Int J Radiat Oncol Biol Phys 86:930\u2013935","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"728_CR6","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205\u2013216","journal-title":"J Natl Cancer Inst"},{"key":"728_CR7","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","volume":"17","author":"BD Cheson","year":"1999","unstructured":"Cheson BD, Horning SJ, Coiffier B et al (1999) Report of an international workshop to standardize response criteria for non-Hodgkin\u2019s lymphomas. NCI Sponsored International Working Group. J Clin Oncol 17:1244","journal-title":"J Clin Oncol"},{"key":"728_CR8","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1269\/jrr.46.241","volume":"46","author":"I Skvortsova","year":"2005","unstructured":"Skvortsova I, Popper BA, Skvortsov S et al (2005) Pretreatment with rituximab enhances radiosensitivity of non-Hodgkin\u2019s lymphoma cells. J Radiat Res 46:241\u2013248","journal-title":"J Radiat Res"}],"container-title":["Strahlentherapie und Onkologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-014-0728-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00066-014-0728-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-014-0728-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,13]],"date-time":"2019-08-13T12:21:55Z","timestamp":1565698915000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00066-014-0728-8"}},"subtitle":["Ergebnisse der FORT-Studie"],"short-title":[],"issued":{"date-parts":[[2014,8,7]]},"references-count":8,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["728"],"URL":"https:\/\/doi.org\/10.1007\/s00066-014-0728-8","relation":{},"ISSN":["0179-7158","1439-099X"],"issn-type":[{"type":"print","value":"0179-7158"},{"type":"electronic","value":"1439-099X"}],"subject":[],"published":{"date-parts":[[2014,8,7]]}}}